Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial

Xeltis Netherlands United Kingdom United States of America

Preliminary clinical data from Xabg, Xeltis' coronary artery bypass conduit (CABG), demonstrating positive safety and patency In an earlier, separate trial, Xabg recently demonstrated patency with excellent flow in a 24-month trial – the first time ever this duration has been achievedSupports potential of Xabg to transform CABG surgery landscape and eliminate need for vein harvestingView original content:https://www.prnewswire.co.uk/news-releases/xeltis-announces-positive-data-for-xabg-its-coronary-artery-bypass-conduit-in-eu-clinical-trial-302507017.html